Clinical Trial Detail

NCT ID NCT02367794
Title A Phase III Study of MPDL3280A (Anti-PD-L1) in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-paclitaxel Compared With Carboplatin + Nab-paclitaxel in Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements no
Sponsors Hoffmann-La Roche
Indications

non-small cell lung carcinoma

Therapies

Carboplatin

nab-paclitaxel

Paclitaxel

Atezolizumab

Age Groups: adult

No variant requirements are available.